Stock OGN ORGANON & CO.
Add to a list
To use this feature you must be a member
Log inSign up

Organon & Co. Stock

Equities

OGN

US68622V1061

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 04:00:02 2024-05-28 pm EDT 		5-day change 1st Jan Change
20.98 USD -0.05% Intraday chart for Organon & Co. -3.98% +45.49%
May. 24 Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation MT
May. 24 Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications for Hlx14 CI

Financials (USD)

Sales 2024 * 6.39B Sales 2025 * 6.47B Capitalization 5.4B
Net income 2024 * 751M Net income 2025 * 971M EV / Sales 2024 * 2.04 x
Net Debt 2024 * 7.64B Net Debt 2025 * 6.93B EV / Sales 2025 * 1.91 x
P/E ratio 2024 *
7.24 x
P/E ratio 2025 *
5.6 x
Employees 10,000
Yield 2024 *
5.3%
Yield 2025 *
5.51%
Free-Float 99.84%
More Fundamentals * Assessed data

Chart Organon & Co.

Dynamic Chart

Latest news about Organon & Co.

Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation MT
Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications for Hlx14 CI
Organon & Co and Organon Foreign Debt Co-Issuer B.V Closes Their Previously Announces Private Offering of $500 Million of 6.750% Senior Secured Notes Due 2034 and $500 Million of 7.875% Senior Unsecured Notes Due 2034 CI
Organon Reports Pricing of $1 Billion Senior Notes Offering MT
Organon & Co. and Organon Foreign Debt Co-Issuer B.V. Announces Pricing of $1.0 Billion Senior Notes Offering CI
Organon Plans Offerings of Secured, Unsecured Senior Notes Totaling $1 Billion MT
Organon & Co. and Organon Foreign Debt Co-Issuer BV Announces Proposed $1.0 Billion Senior Notes Offering CI
Organon's Q1 Adjusted Earnings, Revenue Rise; 2024 Revenue Guidance, Quarterly Dividend Maintained MT
Transcript : Organon & Co., Q1 2024 Earnings Call, May 02, 2024
Earnings Flash (OGN) ORGANON & CO. Reports Q1 Revenue $1.62B, vs. Street Est of $1.56B MT
Earnings Flash (OGN) ORGANON & CO. Reports Q1 EPS $1.22, vs. Street Est of $0.93 MT
Organon & Co. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Organon & Co. Provides Earnings Guidance for the Year 2023 CI
Organon & Co Declares Quarterly Dividend on Common Stock, Payable on June 13, 2024 CI
Piper Sandler Raiises Price Target on Organon to $24 From $22, Maintains Overweight Rating MT
More news

Latest transcript on Organon & Co.

Logo Organon & Co.
Organon & Co., Q1 2024 Earnings Call, May 02, 2024
More transcripts

Analyst Recommendations on Organon & Co.

Piper Sandler Raiises Price Target on Organon to $24 From $22, Maintains Overweight Rating MT
Morgan Stanley Lifts Price Target on Organon to $18 From $17, Keeps Equalweight Rating MT
Goldman Sachs Adjusts Price Target on Organon to $18 From $16, Keeps Neutral Rating MT
Piper Sandler Adjusts Organon & Co.'s Price Target to $22 From $32, Maintains Overweight Rating MT
Goldman Sachs Downgrades Organon to Neutral From Buy, Cuts Price Target to $16 From $33 MT
More recommendations

Press releases Organon & Co.

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 BU
Organon Announces Pricing of $1.0 Billion Senior Notes Offering BU
Organon Announces Proposed $1.0 Billion Senior Notes Offering BU
Organon : Q1 2024 Transcript PU
Organon : Q1 2024 Earnings Presentation PU
More press releases

News in other languages on Organon & Co.

La Agencia Europa de Medicamentos (EMA) ha validado las solicitudes de Henlius y Organon para el candidato a biosimilar HLX14 de Prolia ® y Xgeva ® (denosumab)
L’Agence européenne des médicaments (EMA) entérine les dépôts de Henlius et d’Organon pour le candidat biosimilaire HLX14 de Prolia ® et Xgeva ® (denosumab)
Europäische Arzneimittel-Agentur (EMA) validiert Einreichungen von Henlius und Organon für den Prolia ® und Xgeva ® (Denosumab) Biosimilar-Kandidaten HLX14
El estudio clínico comparativo de fase 3 del candidato a biosimilar de Prolia ® y Xgeva ® (denosumab) HLX14 alcanzó los criterios de valoración primarios
Klinische Phase-3-Vergleichsstudie zwischen Prolia ® und Xgeva ® (Denosumab) - Biosimilar-Kandidat HLX14 erreicht primäre Endpunkte
More news

Quotes and Performance

1 day-1.69%
1 week-3.58%
Current month+12.79%
1 month+13.15%
3 months+16.35%
6 months+83.64%
Current year+45.56%
More quotes

Highs and lows

1 week
20.90
Extreme 20.9
21.98
1 month
18.11
Extreme 18.11
21.98
Current year
13.65
Extreme 13.65
21.98
1 year
10.84
Extreme 10.835
24.08
3 years
10.84
Extreme 10.835
39.48
5 years
10.84
Extreme 10.835
39.48
10 years
10.84
Extreme 10.835
39.48
More quotes

Managers and Directors - Organon & Co.

Managers TitleAgeSince
Kevin Ali CEO
 Chief Executive Officer 63 21-06-01
Matthew Walsh DFI
 Director of Finance/CFO 57 21-06-01
Juan Camilo Arjona Ferreira CTO
 Chief Tech/Sci/R&D Officer 54 23-09-04
Members of the board TitleAgeSince
Rochelle Lazarus BRD
 Director/Board Member 76 21-06-01
Carrie Cox CHM
 Chairman 66 21-06-01
Robert Essner BRD
 Director/Board Member 76 21-06-01
More insiders

ETFs positioned on Organon & Co.

Name Weight AuM 1st Jan change Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
15.92% 254 M€ +13.10% -
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED ETF First Trust AlphaDEX U.S. Health Care Sector Index ETF - CAD Hedged
1.71% 2 M€ 0.00%
More ETFs positioned on Organon & Co.

Quotes

Date Price Change Volume
24-05-28 20.98 -0.05% 1 190 217
24-05-24 20.99 -1.69% 1,043,753
24-05-23 21.35 -2.78% 1,679,297
24-05-22 21.96 +0.50% 1,437,782
24-05-21 21.85 +0.37% 1,525,522

Delayed Quote Nyse, May 24, 2024 at 04:00 pm EDT

More quotes

Company Profile

Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
Sector
Pharmaceuticals
Calendar
2024-06-04 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Ratings for Organon & Co.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
20.99 USD
Average target price
22.5 USD
Spread / Average Target
+7.19%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ORGANON & CO. Stock Organon & Co.
+45.56% 5.4B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.74% 594B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
NOVARTIS AG Stock Novartis AG
+8.44% 205B
ROCHE HOLDING AG Stock Roche Holding AG
-5.97% 203B
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. OGN Stock